4-year results from the RAPID-PsA phase 3 randomised placebo-controlled trial of certolizumab pegol in psoriatic arthritis
D Van Der Heijde, A Deodhar, O FitzGerald… - RMD open, 2018 - rmdopen.bmj.com
Objective To report the efficacy, patient-reported, radiographic and safety outcomes of 4
years' certolizumab pegol (CZP) treatment in patients with psoriatic arthritis (PsA). Methods …
years' certolizumab pegol (CZP) treatment in patients with psoriatic arthritis (PsA). Methods …
The impact of certolizumab pegol treatment on the incidence of anterior uveitis flares in patients with axial spondyloarthritis: 48-week interim results from C-VIEW
I Van der Horst-Bruinsma, R Van Bentum… - RMD open, 2020 - rmdopen.bmj.com
Background Acute anterior uveitis (AAU) is the most common extra-articular manifestation in
patients with axial spondyloarthritis (axSpA). C-VIEW investigates the impact of the Fc-free …
patients with axial spondyloarthritis (axSpA). C-VIEW investigates the impact of the Fc-free …
Reduction of anterior uveitis flares in patients with axial spondyloarthritis on certolizumab pegol treatment: final 2-year results from the multicenter phase IV C-VIEW …
IE van der Horst-Bruinsma… - Therapeutic …, 2021 - journals.sagepub.com
Introduction: Acute anterior uveitis (AAU), affecting up to 40% of patients with axial
spondyloarthritis (axSpA), risks permanent visual deficits if not adequately treated. We report …
spondyloarthritis (axSpA), risks permanent visual deficits if not adequately treated. We report …
POS0897 REDUCTION OF ANTERIOR UVEITIS FLARES IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS DURING CERTOLIZUMAB PEGOL TREATMENT: 96 …
I Van der Horst-Bruinsma, R Van Bentum, F Verbraak… - 2021 - ard.bmj.com
Background: Acute anterior uveitis (AAU) is the most common extra-articular manifestation in
axial spondyloarthritis (axSpA), affecting up to 40% of patients and causing significant …
axial spondyloarthritis (axSpA), affecting up to 40% of patients and causing significant …
[HTML][HTML] The Impact of Certolizumab Pegol Treatment on the Incidence of Anterior Uveitis Flares in Patients with Axial Spondyloarthritis: Responses by Gender
B Hoepken, I van der Horst-Bruinsma… - … & Visual Science, 2020 - iovs.arvojournals.org
Purpose: Acute anterior uveitis (AAU) is the most common extra-articular manifestation in
patients (pts) with axial spondyloarthritis (axSpA). Male pts have been shown to be more …
patients (pts) with axial spondyloarthritis (axSpA). Male pts have been shown to be more …
FRI0333 ACHIEVEMENT OF VERY LOW DISEASE ACTIVITY AND REMISSION TREATMENT TARGETS IS ASSOCIATED WITH REDUCED RADIOGRAPHIC …
Background: Several disease activity measures and thresholds have been recommended as
psoriatic arthritis (PsA) treatment targets, although consensus on the most appropriate …
psoriatic arthritis (PsA) treatment targets, although consensus on the most appropriate …
[CITATION][C] Reduction of anterior uveitis flares in patients with axial spondyloarthritis following 1 year of treatment with certolizumab pegol: 48-week interim results …
I van der Horst-Bruinsma… - ARTHRITIS & …, 2019 - … ST, HOBOKEN 07030-5774, NJ USA
[CITATION][C] Dual Neutralization of IL-17A and IL-17F with Bimekizumab in Patients with Active Psoriatic Arthritis: Disease Activity and Remission in a 48-Week Phase …
P Mease, L Gossec, L Coates… - ARTHRITIS & …, 2019 - … ST, HOBOKEN 07030-5774, NJ USA